Positive results from Sanofi and Regeneron’s SAR236553/REGN727 Phase 2 trial on heFH
Sanofi and Regeneron Pharmaceuticals, Inc. today announced additional positive results from a Phase 2 trial of SAR236553/REGN727 in patients with heterozygous familial hypercholesterolemia (heFH).